Depixus, a pioneer in the field of intereactomics, has been awarded the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at their annual International Conference and Exhibition in Boston, MA. The award was presented to the company alongside the unveiling of their groundbreaking MAGNA One™ instrument at the conference.
The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Depixus was one of just 16 companies selected to participate in SLAS2024’s Innovation AveNEW program, a dedicated area for start-ups and emerging companies within the conference. From this group, eight companies were chosen as finalists for the award, with Depixus being among them.
MAGNA One is based on magnetic force spectroscopy, allowing for high-throughput analysis of dynamic biomolecular interactions. This technology provides real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for studying challenging targets such as RNA and protein-protein interactions. The insights gained from this technology can accelerate disease mechanisms and aid in the development of new therapeutics.
Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the importance of their innovative technology and its potential to impact understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this achievement coincides perfectly with their launch of their technology access program and commercial rollout of MAGNA One, marking a significant moment for Depixus’ growth as a company.
For more information about Depixus or MAGNA One, visit depixus.com or contact Steve Klose at email@example.com